SEC Form 4 · accession 0001209191-18-037434

GLOBUS MEDICAL INC · GMED

Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗

Reporting owner

Anthony L Williams

Officer — President

Period of report

Jun 11, 2018

Accepted (ET)

Jun 13, 2018 · 4:02 pm EDT

Rule 10b5-1 plan

unknown — predates the checkbox

Issuer CIK

0001237831

Table I — non-derivative securities

Security	Date	Code	Shares	Price	A/D	Owned after	D/I
Class A Common Stock	Jun 11, 2018	M	10,000	$13.04	A	10,000	D
Class A Common Stock	Jun 11, 2018	M	30,000	$23.95	A	40,000	D
Class A Common Stock	Jun 11, 2018	M	40,000	$24.42	A	80,000	D
Class A Common Stock	Jun 11, 2018	M	41,667	$24.10	A	121,667	D
Class A Common Stock^F2	Jun 11, 2018	S	120,267	$56.1353	D	1,400	D
Class A Common Stock^F3	Jun 11, 2018	S	1,400	$56.872	D	0	D

Table II — derivative securities

Security	Conv. / exercise price	Date	Code	Shares	A/D	Exercisable	Expires	Underlying	Underlying shares	Owned after	D/I
Stock Option (Right to Buy Class A Common Stock)^F4	$13.04	Jun 11, 2018	M	10,000	D	—	Jan 24, 2023	Class A Common Stock	10,000	0	D
Stock Option (Right to Buy Class A Common Stock)^F5	$23.95	Jun 11, 2018	M	30,000	D	—	Jan 23, 2024	Class A Common Stock	30,000	0	D
Stock Option (Right to Buy Class A Common Stock)^F6	$24.42	Jun 11, 2018	M	40,000	D	—	Jun 23, 2024	Class A Common Stock	40,000	0	D
Stock Option (Right to Buy Class A Common Stock)^F7	$24.10	Jun 11, 2018	M	41,667	D	—	Jan 20, 2025	Class A Common Stock	41,667	8,333	D

Explanation of responses

F1This sale was effected pursuant to a Rule 10b5-1 trading plan executed by the reporting person.
F2The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $55.83 to $56.74, inclusive. The reporting person undertakes to provide the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnote (2) to this Form 4.
F3The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $56.835 to $56.925, inclusive. The reporting person undertakes to provide the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnote (3) to this Form 4.
F4These options were granted on January 24, 2013, and vested over a four-year period with one-fourth (1/4) of the options granted vesting on January 1, 2014, the first anniversary of the vesting commencement date, and the balance of the options granted vesting ratably on a monthly basis over the following 36 months.
F5These options were granted on January 23, 2014, and vest over a four-year period with one-fourth (1/4) of the options granted vesting on January 1, 2015, the first anniversary of the vesting commencement date, and the balance of the options granted vesting ratably on a monthly basis over the following 36 months.
F6These options were granted on June 23, 2014, and vest over a four-year period with one-fourth (1/4) of the options granted vesting on May 1, 2015, the first anniversary of the vesting commencement date, and the balance of the options granted vesting ratably on a monthly basis over the following 36 months.
F7These options were granted on January 20, 2015, and vest over a four-year period with one-fourth (1/4) of the options granted vesting on January 1, 2016, the first anniversary of the vesting commencement date, and the balance of the options granted vesting ratably on a monthly basis over the following 36 months.